LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1
Malvi P, Janostiak R, Chava S, Manrai P, Yoon E, Singh K, Harigopal M, Gupta R, Wajapeyee N. LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. Oncogenesis 2020, 9: 77. PMID: 32859889, PMCID: PMC7455732, DOI: 10.1038/s41389-020-00263-1.Peer-Reviewed Original ResearchTriple-negative breast cancerLIM domain kinase 2Metastatic progressionPharmacological inhibitionBreast cancerTNBC cellsMetastatic attributesMetastatic breast cancer subtypesSerine/arginine protein kinasesPrimary tumor growthBreast cancer subtypesKinase 2Serine/threonine kinaseActin filament dynamicsStable isotope labelingShort hairpin RNASystemic therapyProtein kinase 1Therapeutic optionsHER2 expressionLarge-scale phosphoproteomic analysisTNBC metastasisTumor growthCancer subtypesSR family